Drugs / TAEST16001 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04318964 | Mar 2020 → Apr 2022 | soft tissue sarcoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAEST16001 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318964 ↗ |
| Known as | TAEST16001 | “The purpose of this study is to evaluate the safety, tolerance, PK, PD characteristics, and preliminary efficacy of TAEST16001 immunotherapy in the treatment of patients with...” NCT04318964 ↗ |
| Action | Deplete | “which can kill tumor cell internal antigen” NCT04318964 ↗ |
| Modality | Cell therapy | “TCR-T cell treatment developed by the applicant” NCT04318964 ↗ |
| Route | Intravenous | “received the intravenous reinfusion of TAEST16001 cells” NCT04318964 ↗ |